

**COMPARISON OF CURRENT 180 NAC 7 “MEDICAL USE OF RADIOACTIVE MATERIALS” DATED JULY 11, 2009
TO PREVIOUS 180 NAC 7 DATED April 12, 2003 and 10 CFR 35**

CURRENT 180 NAC 7 DATED JULY 11, 2009		PREVIOUS 180 NAC 7 DATED 4-12-2003	
Use of Radioactive Material	Training	Use of Radioactive Material	Training
7-041 Use of Unsealed Radioactive Material for Uptake, Dilution, and Excretion Studies for Which a Written Directive is Not Required (10CFR 35.100)	7-043 Training for Uptake, Dilution, and Excretion Studies (10CFR 35.190)	7-034 Use of Unsealed Radioactive Material for Uptake, Dilution, and Excretion Studies	7-066.02 Training for Uptake, Dilution, and Excretion Studies
7-044 Use of Unsealed Radioactive Material for Imaging and Localization Studies For Which a Written Directive is Not Required (10 CFR 35.200)	7-047 Training for Imaging and Localization Studies (10 CFR 25.290)	7-036 Use of Unsealed Radioactive Material for Imaging and Localization Studies	7-066.03 Training form Imaging and Localization Studies
7-048 Use of Unsealed Radioactive Material for Which a Written Directive is Required (10CFR 35.300)	7-051 Training for use of Unsealed Radioactive Material for Which a Written Directive is required (10 CFR 35.390)	7-040 Use of Unsealed Radioactive Material for Therapeutic Administration	7-066.04 Training for Therapeutic Use of Unsealed Radioactive Material
	7-052 Training for the Oral Administration of Sodium Iodide I-131 in Quantities Less than 1.22 GBq (33 mCi for Which a Written Directive is Required) (10CFR 35.392)	7-040, item 1 Use of Unsealed Radioactive Material for Therapeutic Administration – I-131 as iodide for treatment of hyperthyroidism, cardiac dysfunction;	
	7-053 Training for the Oral Administration of Sodium Iodide I-131 in Quantities Greater than 1.22 GBq (33 mCi) for Which a Written Directive is Required (10 CFR 35.394)	7-040, item 2 Use of Unsealed Radioactive Material for Therapeutic Administration – I-131 as iodide for treatment of thyroid carcinoma;	
	7-054 Training for the Parenteral Administration of Unsealed Radioactive Material Requiring a Written Directive (10 CFR 35.396)	7-040 items 3-7, Use of Unsealed Radioactive Material for Therapeutic Administration – P-32 as soluble phosphate for treatment of polycythemia vera, leukemia, and bone metastases; P-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions; Gold-198 as	

CURRENT 180 NAC 7 DATED JULY 11, 2009		PREVIOUS 180 NAC 7 DATED 4-12-2003	
Use of Radioactive Material	Training	Use of Radioactive Material	Training
		colloid for intracavitary treatment of malignant effusions;	
7-055 Use of Sources for Manual Brachytherapy (10 CFR 35.400)	7-063 Training for Use of Manual Brachytherapy Sources (10 CFR 35.490)	7-046 Use of sources for Brachytherapy	7-066.06 Training for Use of Brachytherapy Sources
	7-064 Training for Ophthalmic Use of Strontium-90 (10 CFR 35.491)	7-046 Use of sources for Brachytherapy – Item 8 Strontium -90	7-066.07 Training for Ophthalmic Use of Strontium-90
7-065 Use of Sealed Sources for Diagnosis (10 CFR 35.500)	7-066 Training for use of Sealed Sources for Diagnosis (10 CFR 35.590)	7-044 Use of Sources for Diagnosis	7-066.08 Training for Use of sealed Sources for Diagnosis
7-067 Use of a Sealed Source in a Remote Afterloader Units, Teletherapy Units, and Gamma Stereotactic Radiosurgery Units (10 CFR 35.600)	7-084 Training for use of Remote Afterloader Units, and Gamma Stereotactic Radiosurgery Units (10 CFR 35.690)	7-052 Use of a Sealed Source in a Teletherapy Unit	7-066.09 Training for Teletherapy
7-085 Other Medical Uses of Radioactive Material or Radiation from Radioactive Material (10 CFR 35.1000)	NA	NA	